: iStockAnalyst.com Symbols Feed

Earnings Preview For Sep 28 - Oct 2 - Earnings Preview

Sat, 26 Sep 2009 05:03:14 GMT

Five S&P 500 companies are confirmed to report: Constellation Brands (STZ), Darden Restaurants (DRI), Jabil Circuit (JBL), Nike (NKE) and Walgreen (WAG). A total of 27 companies are on the calendar.[More...]

Immucor Posts Record Revenues in FY09

Fri, 24 Jul 2009 16:04:43 GMT

Immucor (BLUD) reported net income of $19.4 million, or $0.27 per diluted share, for the fourth quarter of FY 2009, compared to $18.3 million, or $0.26 per diluted share, a year ago. Revenues grew 15.2% to $79.0 million on higher price and volume. Revenues include a negative forex impact of around $3 million y-o-y.? Gross margin contracted to 69.9% from 72.0%, mainly due to $1.8 million of expense incurred on the Quality Process Improvement Project. Operating expenses grew 22.9% to $26.1 million, primarily resulting from the takeover of BioArray and direct marketing initiatives in the France and United Kingdom. R&D grew 117.9% to $3.1 million (4.0% of revenues) and SGA grew 11.1% to $21.9 million (27.6% of revenues).? Reagents revenues grew 14.8% to $69.2 million – Traditional Reagents contributed $52.1 million[More...]

Looking For Solid, Growing Companies In A Recession

Mon, 29 Jun 2009 12:33:44 GMT

In dedication to my recent posts on value investing vs. trading strategies, I decided to focus this week’s screen to the market’s favorite word: growth. Specifically, the criteria used was positive revenue growth for the next fiscal year. Of course, this does not translate to earnings growth but management teams should have figured out there’s (...)[More...]

Barry Rosenstein's Jana Partners Files 13G on Immucor (BLUD)

Wed, 10 Jun 2009 16:16:00 GMT

In a recent 13G filed with the SEC, hedge fund Jana Partners has disclosed a 5.5% ownership stake in Immucor (BLUD). They now own 3,865,413 shares and this is a brand new position for them, as they previously did not hold it as of March 31st, 2009 (per their last 13F filing). So, after all this time, Jana appears to be alive and well and buying stocks.[More...]

Wall Street Slumps On Earnings Jitters, GM Sinks

Tue, 07 Apr 2009 21:30:00 GMT

US stocks retreated on Tuesday as investors grew nervous ahead of first-quarter earnings season.[More...]

US Stock Futures Drop On Earnings Fear, Alcoa In Focus

Tue, 07 Apr 2009 12:36:00 GMT

US stock futures plunged on Tuesday as investors remained concerned ahead of aluminum giant Alcoa’s earnings report. Fresh fears about the health of banking system also weighed upon futures.[More...]

Immucor (BLUD): A Buy In Blood Testing

Mon, 09 Feb 2009 14:05:00 GMT

"We’ve built a successful trading strategy based on the simple concept that you can profit by buying into stronger sectors and avoiding weaker ones," says Brandon Clay. In his Invest with an Edge he explains, "For example, so far in 2009, the financials have lost –17.7% while health care has climbed 1% over the same period." Further, he looks for the strongest stocks in the strongest sectors, such as his latest buy, [More...]

Earnings Review: January 7, 2009

Thu, 08 Jan 2009 00:15:40 GMT

Late on Wednesday, home-furnishings retailer, Bed Bath & Beyond Inc. (NASDAQ: BBBY) announced that third quarter net income plunged about 37% to $87.7 million or 34 cents a share from $138.2 million or 52 cents a share in the year ago quarter.[More...]

Earnings Preview for Jan 5 - 9 - Earnings Preview

Fri, 02 Jan 2009 18:59:00 GMT

Immucor, Inc. (BLUD) could top expectations. Bed Bath & Beyond Inc. (BBBY) and Global Payments Inc. (GPN) could miss estimates. Traders and portfolio managers returning from their holiday vacations will be greeted by earnings and economic news. Though earnings season will not officially start for another week (Alcoa Inc. ([More...]

Medical Devices

Wed, 26 Nov 2008 21:58:00 GMT

In previous bear markets, investments in medical device stocks were a good way to play the downturn. Unfortunately, many medical device companies have been also negatively impacted by the current economic slowdown. Medical device companies have been more sensitive to this economy as a result of the additional impact from the credit crunch. As a result of the recent tightening of credit markets and concerns regarding the availability of credit, particularly in the United States, uncertainty exists in the extent of healthcare providers' ability to purchase capital equipment. Thus, the credit crunch may have a significant impact on the ability of customers to secure adequate funding to buy medical device products or might cause purchasing decisions to be delayed. Consequently, revenues of medical device companies may be negatively impacted from the inability of customers to purchase products, ability of customers to purchase a limited quantity, or the[More...]

Stocks Finish Mostly Lower

Mon, 29 Jun 2009 14:46:00 GMT

Stocks finished the week mostly lower following Thursday's rally.
The Nasdaq managed to edge higher as tech stocks moved up on better-than-expected earnings news from Palm (PALM).
Among stocks in the news, Palm (PALM) shares jumped after the company reported $0.40 fourth quarter adjusted loss, vs. $0.22 loss a year ago, on 62% revenue decline.

[More...]

KB Home, Palm, UBS, Immucor are big movers

Fri, 26 Jun 2009 21:49:00 GMT

NEW YORK - Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and Nasdaq Stock Market:
The homebuilder reported a big jump in new house orders from the previous quarter, but posted a bigger loss than analysts had expected.
The industrial equipment maker said its orders dropped in the third quarter and issued guidance below Wall Street expectations.

[More...]

Shalov Stone Bonner & Rocco LLP Announces Class Action Against Immucor, Inc.

Thu, 27 Aug 2009 23:48:00 GMT

NEW YORK, NY -- -- 08/27/09 -- Shalov Stone Bonner & Rocco LLP announces that a class action lawsuit has been filed on behalf of all purchasers of the publicly traded securities of Immucor, Inc. between October 19, 2005 and April 23, 2009 , who were damaged thereby. The lawsuit is pending in the United States District Court for the Northern District of Georgia against Immucor and certain of its officers and directors.[More...]

Immucor Announces 2 Million Share Increase to Stock Repurchase Program

Tue, 18 Aug 2009 20:05:00 GMT

Immucor, Inc. , a global leader in providing automated instrument-reagent systems to the blood transfusion industry, today announced that its board of directors has authorized an additional 2 million common shares for repurchase under its current stock repurchase program.[More...]

Immucor Submits 30-Day Response to FDA; Organizational Realignment Supports Quality Initiatives

Mon, 10 Aug 2009 20:17:00 GMT

Immucor, Inc. , a global leader in providing automated instrument-reagent systems to the blood transfusion industry, today announced the submission of its formal 30 working day response to the Food and Drug Administration's administrative action, which was announced on June 26, 2009.[More...]

Immucor Announces Fiscal Fourth Quarter Results

Thu, 23 Jul 2009 20:01:00 GMT

Immucor, Inc. , a global leader in providing automated instrument-reagent systems to the blood transfusion industry, today reported financial results for the fiscal fourth quarter ended May 31, 2009. Fourth Quarter Financial HighlightsRevenue for the fiscal fourth quarter of 2009 was $79.0 million, up 15% from $68.6 million in the same period last year. Gross margin was 69.9% in the quarter, compared with 72.0% in the prior year quarter. Current quarter gross margin included expenses of approximately $1.8 million related to the Quality Process Improvement Project.Net income in the quarter was $19.4 million, compared with $18.3 million for the same quarter last year. Diluted earnings per share totaled $0.27 in the quarter, compared with $0.26 for the same period last year. The current year quarter included the impact from the Quality Process Improvement Project of approximately $0.02 per diluted share, net of tax. The current year quarter included the results of BioArray Solutions, which was acquired on August 4, 2008.Full Year Results For fiscal 2009, revenue was $300.5 million, up 15% from $261.2 million in the prior year. Gross margin was 71.9%, up from 71.0% in the prior year. Full year gross margin included expenses related to the Quality Process Improvement Project of approximately $2.4 million. Net income was $76.2 million, or $1.07 per diluted share, compared with $71.5 million, or $1.00 per diluted share in the prior year. Fiscal 2009 included expenses related to the Quality Process Improvement Project of approximately $0.02 per diluted share, net of tax. Cash flow from operations for the year ended May 31, 2009 was $79.8 million, compared with $75.1 million in the prior year.The current year financials included 10 months of results for BioArray. 'For fiscal 2009, we achieved record revenue, earnings and cash flow from operations,' stated Dr. Gioacchino De Chirico, Immucor's President and Chief Executive Officer. 'Our growth has been driven by the success of our automation strategy combined with the fact that our reagent product offering is necessary to ensure the safety of transfusions.' Selected Product Revenue and Gross Margin[More...]

Immucor Appoints Chief Operating Officer

Thu, 16 Jul 2009 20:10:00 GMT

Immucor, Inc. , a global leader in providing automated instrument-reagent systems to the blood transfusion industry, today announced that Geoffrey S. Crouse has been named Vice President and Chief Operating Officer. In this newly created position, Mr. Crouse will have worldwide responsibility for manufacturing and distribution as well as sales, marketing and customer service. Mr. Crouse will report to Dr. Gioacchino De Chirico, Immucor's President and Chief Executive Officer.Mr. Crouse previously served as vice president of the life sciences business at Millipore Corporation, a NYSE-traded provider of technologies, tools and services for the global life science industry. In this role, he led the Life Science Strategic Business Unit, a global laboratory consumables and reagents business, and held responsibility for manufacturing, research and development, sales and marketing. During his tenure, Mr. Crouse improved manufacturing operations, led multiple acquisitions and integrations while increasing sales and profitability for the business unit.'We are pleased to strengthen our management team with the addition of Geoff,' stated Dr. De Chirico. 'His experience and results-oriented track record will enhance our efforts to improve transfusion medicine through automation. Our commitment to improving blood bank operations and patient safety benefits our customers, employees and shareholders.' Mr. Crouse's experience includes various leadership roles in both the U.S. and internationally. Prior to joining Millipore, Mr. Crouse worked at Roche, a Swiss Exchange-traded leader in the pharmaceuticals and diagnostics industries, where he most recently led market development and government affairs for the diagnostics division based in Basil, Switzerland. Mr. Crouse holds a Masters of Business and a Masters of Public Health from the University of California, Berkeley as well as a Bachelor of Arts degree from Boston College.About ImmucorFounded in 1982, Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of automated instrumentation for all of its market segments. For more information on Immucor, please visit our website at www.immucor.com.[More...]

Immucor Submits 10-Day Response to FDA; Establishes Product Surveillance and Improvement Department

Mon, 13 Jul 2009 20:00:00 GMT

Immucor, Inc. , a global leader in providing automated instrument-reagent systems to the blood transfusion industry, today announced the submission of its formal 10 working day response to the Food and Drug Administration's administrative action, which was announced on June 26, 2009. This formal 10-day response reiterates the Company's commitment to implement corrective actions that not only address the FDA's noted deficiencies but also establish a world-class quality system. The Company will provide its detailed remediation plan and timelines in its 30 working day response to the FDA no later than August 11, 2009.'We take our regulatory responsibilities very seriously. We began our Quality Process Improvement Project in early 2009 to bring our quality system up to world-class standards,' stated Dr. Gioacchino De Chirico, Immucor's President and Chief Executive Officer. 'We remain committed to completing this Project as quickly as possible.' Immucor previously announced that it had received a notice of intent to revoke its biologics license from the FDA with respect to its Reagent Red Blood Cells and Anti-E Blood Grouping Reagent products. This administrative action was based on a January 2009 inspection. The notice has a revised effective date of June 30, 2009. The FDA has not ordered the recall or banned the sale of any of the Company's products. New Product Surveillance and Improvement Department EstablishedThe Company also announced today the creation of a Product Surveillance and Improvement Department to support the quality system initiative underway. With a focus on product quality, this new department will provide a single internal focal point to monitor quality issues, whether identified through internal or external sources, and initiate the appropriate corrective actions. 'We will continue to evaluate our operations and organization to ensure they are in line with our commitment to develop high quality systems,' stated Dr. De Chirico. 'Our new Product Surveillance and Improvement Department is an important example of our drive to modernize our quality approach.'About ImmucorFounded in 1982, Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of automated instrumentation for all of its market segments. For more information on Immucor, please visit our website at www.immucor.com.[More...]

Immucor to Announce Fiscal Fourth Quarter Financial Results on Thursday, July 23, 2009

Thu, 09 Jul 2009 12:26:00 GMT

Immucor, Inc. , a global leader in providing automated instrument-reagent systems to the blood transfusion industry, today announced that it will release its fiscal fourth quarter earnings on Thursday, July 23, 2009 after the market close. The Company will host a conference call on Friday, July 24, 2009 at 8:30 a.m. to discuss the results.[More...]

Immucor Responds To FDA Notice

Fri, 26 Jun 2009 12:33:00 GMT

Immucor Responds To FDA Notice[More...]

Immucor Announces Fiscal Year 2010 Guidance

Mon, 01 Jun 2009 21:09:00 GMT

NORCROSS, Ga., June 1 /PRNewswire-FirstCall/ -- Immucor, Inc. , a global leader in providing automated instrument-reagent systems to the blood transfusion industry, today announced its guidance for its fiscal year ending May 31, 2010.
Of the Company's Capture(R) and traditional reagent revenue, approximately two-thirds of the revenue is under contract.
The Company expects to complete the project during the third fiscal quarter of 2010.

[More...]

Immucor and Alverno Clinical Laboratories Sign Five-Year Automation Agreement

Wed, 27 May 2009 19:58:00 GMT

Immucor, Inc. , a global leader in providing automated instrument-reagent systems to the blood transfusion industry, announced today that it has signed a five-year agreement with Alverno Clinical Laboratories, LLC, one of the largest regional hospital laboratory integrated delivery systems in the nation, serving 27 hospitals in Illinois and Indiana.[More...]